Breast and gynecologic cancers
35 public biotech companies we cover are developing treatments for breast, ovarian, endometrial and cervical cancer. 12 upcoming catalysts are listed below, with dates as the companies gave them.
Companies
- Acrivon Therapeutics (ACRV)Thesis Intact
Endometrial cancer
- Actinium Pharmaceuticals (ATNM)Thesis Challenged
Breast cancer
- Allarity Therapeutics (ALLR)Thesis Intact
Ovarian cancer
- ALX Oncology (ALXO)Thesis Challenged
Breast cancer, HER2+ breast cancer
- ArriVent BioPharma (AVBP)Thesis Challenged
Ovarian cancer, Endometrial cancer
- Biohaven (BHVN)Thesis Challenged
Endometrial cancer
- BridgeBio Oncology Therapeutics (BBOT)Thesis Intact
Breast cancer, HER2-positive breast cancer, HER2+ breast cancer, HR+/HER2- breast cancer
- Calidi Biotherapeutics (CLDI)Thesis Challenged
Breast cancer
- Cardiff Oncology (CRDF)Thesis Challenged
Triple negative breast cancer
- Cellectar Biosciences (CLRB)Thesis Challenged
Triple-negative breast cancer
- Compass Therapeutics (CMPX)Thesis Challenged
Triple-negative breast cancer
- Context Therapeutics (CNTX)Thesis Intact
Ovarian cancer, Endometrial cancer, Triple-negative breast cancer, Platinum-resistant ovarian cancer
- Corbus Pharmaceuticals (CRBP)Thesis Intact
Cervical cancer
- CytomX Therapeutics (CTMX)Thesis Intact
Breast cancer
- Delcath Systems (DCTH)Thesis Intact
Breast cancer, Liver-dominant metastatic breast cancer
- Faeth Therapeutics (FTH)Thesis Intact
Breast cancer, Endometrial cancer
- Greenwich LifeSciences (GLSI)Thesis Challenged
Breast cancer, HER2-positive breast cancer
- IDEAYA Biosciences (IDYA)Thesis Intact
Breast cancer, Ovarian cancer
- Immatics (IMTX)Thesis Intact
Ovarian cancer, Uterine cancer
- ImmunityBio (IBRX)Thesis Intact
Triple-negative breast cancer
- Immunocore (IMCR)Thesis Intact
Ovarian cancer, Platinum-resistant ovarian cancer, Platinum-sensitive ovarian cancer
- Immutep (IMMP)Thesis Challenged
Breast cancer
- Imunon (IMNN)Thesis Challenged
Ovarian cancer
- Iovance Biotherapeutics (IOVA)Thesis Intact
Endometrial cancer
- Karyopharm Therapeutics (KPTI)Thesis Challenged
Endometrial cancer
- Monte Rosa Therapeutics (GLUE)Thesis Intact
Breast cancer
- NextCure (NXTC)Thesis Broken
Ovarian cancer, Uterine serous carcinoma
- NovoCure (NVCR)Thesis Challenged
Ovarian cancer
- Personalis (PSNL)Thesis Intact
Early-stage breast cancer
- Precigen (PGEN)Thesis Intact
Cervical cancer
- Recursion Pharmaceuticals (RXRX)Thesis Intact
Ovarian cancer, Endometrial cancer, PI3K H1047R mutant breast cancer
- SELLAS Life Sciences Group (SLS)Thesis Intact
Ovarian cancer
- Summit Therapeutics (SMMT)Thesis Challenged
Triple negative breast cancer
- Verastem (VSTM)Thesis Intact
Low-grade serous ovarian cancer
- Zentalis Pharmaceuticals (ZNTL)Thesis Intact
Ovarian cancer
Drug pages
Upcoming catalysts
Estimated timing · a month, quarter, half-year or year-end the company gave
Expected in Q4 2026
- Q4 2026ACR-368 · Phase 2b enrollment complete (ACR-368-201) · Endometrial cancer · serous all-comer
Expected in H2 2026
- H2 2026ACR-368 · Phase 2b interim results (ACR-368-201) · Endometrial cancer · serous all-comer
- H2 2026BBO-10203 · Results · HER2+ breast cancer, HR+/HER2- breast cancer · PIK3CA mutant, KRAS mutant colorectal cancer
- H2 2026PIKTOR · Phase 2 topline results (FTH-PIK-201) · Advanced endometrial cancer · second-line
- 2H 2026Brenetafusp · Phase 1/2 interim results · Platinum-resistant ovarian cancer · Platinum-sensitive ovarian cancer · NSCLC
- H2 2026REC-7735 · Phase 1 start · PI3K H1047R mutant breast cancer · solid tumors
- H2 2026REC-7735 · REC-102 · Phase 1 start · PI3K H1047R mutant breast cancer · solid tumors · Hypophosphatasia
Expected in Q2 2027
- Q2 2027CTIM-76 · Phase 1a results · Platinum-resistant ovarian cancer
Expected in H1 2027
- H1 2027ACR-368 · Phase 3 start · Endometrial cancer · serous all-comer
- 1H 2027Azenosertib · Phase 2 topline results (DENALI) · Ovarian cancer · platinum-resistant · Cyclin E1-positive
Expected by end of June 2027
- Mid 2027Evorpacept · Phase 2 topline results (ASPEN-09-Breast) · HER2+ breast cancer · previously treated
- Mid 2027AVMAPKI/FAKZYNJA · Phase 3 topline results (RAMP 301) · Recurrent low-grade serous ovarian cancer